

The effect of an antibody (Ab) against human IL-6 in the transplant model of psoriasis.

Published: 09-08-2010

Last updated: 03-05-2024

To see if the new drug can prevent development of psoriatic changes in the transplant model of psoriasis

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Autoimmune disorders
Study type	Observational invasive

Summary

ID

NL-OMON34138

Source

ToetsingOnline

Brief title

The effect of an Ab against IL-6 in the transplant model of psoriasis.

Condition

- Autoimmune disorders
- Epidermal and dermal conditions

Synonym

psoriasis

Research involving

Human

Sponsors and support

Primary sponsor: Argen-X

Source(s) of monetary or material Support: Argen-X

Intervention

Keyword: blood, psoriasis, skin biopsies

Outcome measures

Primary outcome

NVT

Secondary outcome

NVT

Study description

Background summary

5 mm skin bopsies, taken from non-involved skin of a psoriasis patient (volunteer), are transplanted onto immune-deficient mice . They are then injected with white blood cells from the same volunteer to induce the development of a psoriatic lesion in the transplant. A number of standard drugs have been shown to inhibit development of the psoriatic lesion, showing that the model is suitable for developing new drugs for treating psoriasis. Client wishes to test a novel drug in the transplant model.

Study objective

To see if the new drug can prevent development of psoriatic changes in the transplant model of psoriasis

Study design

3x5 mm skin biopsies and 27 ml blood will be taken from non-involved skin of 10 psoriasis patient (volunteer). The biopsy sites will be closed using 1 stitch. After 1 week the stitches will be removed. These materials will be used in the transplant model of psoriasis to test the new drug.

Study burden and risks

The transplant model of psoriasis used is the only in vivo one available for evaluating the probable efficacy of new drugs to treat psoriasis. Donating skin biopsies is not perceived as being painful or taxing by the volunteers and they do not result in significant scarring. Donors consider the potential benefits in developing new therapies to more than compensate for any discomfort.

Contacts

Public

Argen-X

Technologiepark 30
9052 Zwijnaarde
BE

Scientific

Argen-X

Technologiepark 30
9052 Zwijnaarde
BE

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Mild to moderate psoriasis vulgaris

Exclusion criteria

Volunteers can not be taking drugs systemically, including immune-modifiers for other diseases.

Volunteers cannot be undergoing UV/light therapy

Volunteers should not show Kobner phenomenon at wound sites.

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 22-09-2010

Enrollment: 11

Type: Actual

Ethics review

Approved WMO

Date: 09-08-2010

Application type: First submission

Review commission: METC Leiden-Den Haag-Delft (Leiden)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL33124.098.10